Our study found the 5hmC modified genes of critical patients enriched in neutrophil-mediated immunity pathways consistent with previous research indicating that the neutrophil elastase inhibitor (Sivelestat) is a promising therapeutic option in COVID-19 with ARDS (Sahebnasagh et al., 2020). This evidence concerns the gene ELANE and acute respiratory distress syndrome.